What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

[Correspondence] SBRT in oligometastatic castration-resistant prostate cancer

The Lancet Oncology | November 26, 2025 | Vérane Achard, Pierre Blanchard, David Pasquier, Paul Sargos

The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in oligometastatic castration-resistant prostate cancer (mCRPC). This study is the second randomised trial, after the ARTO trial,2 to evaluate this combination. Both PCS-9 and ARTO showed improved radiographical progression-free survival with SBRT. However, a significant…

Topics: prostate-cancer, radiation, clinical-trials, research

Read the full article at The Lancet Oncology